Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease.

By P. Serruys, Felix Unger, J. Sousa, A. Jatene, H. Bonnier, J. Schönberger, N. Buller, Robert Bonser, M. J. Van den brand, L. V. van Herwerden and 2 more. New England Journal of Medicine, 2001

1,192 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/9b3a385425b043b58ae7b820fb628a527ae86236

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. B. de Bruyne
2. T. Engstrøm
3. N. Pijls
4. W. Fearon
5. P. Tonino
6. U. Siebert
7. F. Ikeno
8. M. van ’t Veer

Citations in the corpus

• Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. (2002, background): “Percutaneous coronary intervention has been demonstrated to be at least as effective as coronary artery bypass grafting (CABG) in terms of survival and prevention of myocardial infarction (MI) in appropriately selected patients with either single-vessel or multivessel disease.(2,3) Although PCI achi”
• Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. (2009, methodology): “Patients who had undergone previous PCI were included in the present study, which is often not the case in randomized trials of coronary revascularization.(6,34,37)”